Bone Biologics Corp (BBLG) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2 BURLINGTON WOODS DRIVE, BURLINGTON, MA 01803 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 3/31/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3 | 8 | 7 | 0 | 1 | ||||
| Cash and cash equivalents | 3 | 8 | 7 | 0 | 1 | ||||
| Prepaid expense | 0 | 1 | 0 | 0 | |||||
| Other undisclosed current assets | 1 | ||||||||
| Total current assets: | 4 | 8 | 7 | 0 | 1 | ||||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | ||||||||
| Total noncurrent assets: | 0 | ||||||||
| TOTAL ASSETS: | 4 | 8 | 7 | 0 | 1 | ||||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 0 | 1 | 0 | 0 | 0 | 0 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 0 | 0 | ||||
| Accounts payable | 0 | 0 | 0 | ||||||
| Other undisclosed accounts payable and accrued liabilities | 0 | 1 | 0 | ||||||
| Debt | 0 | ||||||||
| Deferred compensation liability | 0 | 0 | 0 | ||||||
| Due to related parties | ✕ | ✕ | 12 | 9 | |||||
| Other undisclosed current liabilities | 0 | 2 | 1 | 0 | |||||
| Total current liabilities: | 1 | 3 | 0 | 14 | 1 | 10 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 11 | ||||||||
| Due to related parties | ✕ | ✕ | 11 | ||||||
| Total noncurrent liabilities: | 11 | ||||||||
| Total liabilities: | 1 | 3 | 0 | 14 | 12 | 10 | |||
| Equity | |||||||||
| Equity, attributable to parent | 3 | 6 | 7 | (14) | (12) | (9) | |||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Additional paid in capital | 84 | 78 | 77 | 55 | 55 | 55 | |||
| Accumulated deficit | (81) | (72) | (70) | (69) | (67) | (64) | |||
| Total equity: | 3 | 6 | 7 | (14) | (12) | (9) | |||
| TOTAL LIABILITIES AND EQUITY: | 4 | 8 | 7 | 0 | 1 | ||||
Income Statement (P&L) ($ in millions)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,070 | 1,070 | ||||||
| Gross profit: | 1,070 | 1,070 | ||||||
| Operating expenses | (9) | (4) | (1) | (1) | (2) | (3) | ||
| Other undisclosed operating loss | (1,070) | (1,070) | ||||||
| Operating loss: | (9) | (4) | (1) | (1) | (2) | (3) | ||
| Nonoperating income (expense) | 0 | 2 | (1) | (1) | (2) | |||
| Interest and debt expense | (1) | (1) | (1) | (0) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||||||||
| Loss from continuing operations before equity method investments, income taxes: | (9) | (1) | (2) | (2) | (4) | (4) | ||
| Other undisclosed income from continuing operations before income taxes | 1 | 1 | 0 | |||||
| Loss from continuing operations before income taxes: | (9) | (1) | (2) | (2) | (3) | (4) | ||
| Income tax expense | (0) | (0) | (0) | (0) | ||||
| Loss from continuing operations: | (9) | (1) | (2) | (2) | (3) | (4) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (2) | (2) | (3) | (4) | |
| Net loss: | (9) | (1) | (2) | (2) | (3) | (4) | ||
| Other undisclosed net income attributable to parent | ||||||||
| Net loss available to common stockholders, diluted: | (9) | (1) | (2) | (2) | (3) | (4) | ||
Comprehensive Income ($ in millions)
| 3/31/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (9) | (1) | (2) | (2) | (3) | (4) | ||
| Comprehensive loss, net of tax, attributable to parent: | (9) | (1) | (2) | (2) | (3) | (4) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.